<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04044768</url>
  </required_header>
  <id_info>
    <org_study_id>ADP 0044-002</org_study_id>
    <nct_id>NCT04044768</nct_id>
  </id_info>
  <brief_title>Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma</brief_title>
  <official_title>A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adaptimmune</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adaptimmune</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A*02 eligible and&#xD;
      MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1&#xD;
      and Cohort 2) or MRCLS (Cohort 1) .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2034</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Overall Response Rate (ORR)</measure>
    <time_frame>2.5 years</time_frame>
    <description>ORR is defined as incidence of complete responses or partial responses as assessed by RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with treatment -related adverse events (AEs), including serious adverse events (SAEs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0</measure>
    <time_frame>2.5 years</time_frame>
    <description>Determine if treatment with ADP-A2M4 is safe and tolerable through assessment of adverse events (AEs) including Serious Adverse Events (SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate safety of ADP-A2M4 through measurement of Replication -competent Retrovirus in genetically engineered T-cells</measure>
    <time_frame>2.5 years</time_frame>
    <description>Evaluation of RCL using PCR -based assay in peripheral blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of T-cell clonality and insertional oncogenesis in peripheral blood mononuclear cells (PBMCs).</measure>
    <time_frame>2.5 years</time_frame>
    <description>Measurement of T-cell clonality and insertional oncogenesis in peripheral blood mononuclear cells (PBMCs )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Best overall response (BOR)</measure>
    <time_frame>2.5 years</time_frame>
    <description>BOR is per RECIST V1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>2.5 years</time_frame>
    <description>For patients who are observed to respond to ADP-A2M4, the time taken from date of infusion to achieve a partial response or complete response (TTR) is assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>2.5 years</time_frame>
    <description>For patients who are observed to respond to ADP-A2M4, the DoR is the date of initial response (including confirmation) from date of infusion up until disease progression per RECIST v 1.1 or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>2.5 years</time_frame>
    <description>PFS is assessed from date of infusion of ADP-A2M4 up until the date of disease progression per RECIST v1.1 or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>15 years</time_frame>
    <description>OS is assessed from date of infusion of ADP-A2M4 up until the date of patient death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitation of genetically engineered T-cells in PBMCs</measure>
    <time_frame>2.5 years</time_frame>
    <description>Quantitation of genetically engineered T-cells in PBMCs by qPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs</measure>
    <time_frame>2.5 years</time_frame>
    <description>Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitation of genetically engineered T-cells in PBMCs</measure>
    <time_frame>2.5 years</time_frame>
    <description>Quantitation of genetically engineered T-cells in PBMCs by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs</measure>
    <time_frame>2.5 years</time_frame>
    <description>Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs by qPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invitro diagnostic (IVD) assay for screening</measure>
    <time_frame>2.5 years</time_frame>
    <description>Development and validation of the MAGE-A4 antigen expression companion diagnostic assay</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Synovial Sarcoma</condition>
  <condition>Myxoid Liposarcoma</condition>
  <arm_group>
    <arm_group_label>Autologous genetically modified afamitresgene autoleucel (previously ADP-A2M4) SPEAR™ T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>afamitresgene autoleucel (previously ADP-A2M4)</intervention_name>
    <description>Single infusion of autologous genetically modified afamitresgene autoleucel (previously ADP-A2M4) Dose: 1.0 x109 to 10x109 transduced by a single intravenous infusion</description>
    <arm_group_label>Autologous genetically modified afamitresgene autoleucel (previously ADP-A2M4) SPEAR™ T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria&#xD;
&#xD;
          -  Age ≥16 (10 years at selected sites) and &lt;=75 years&#xD;
&#xD;
          -  Diagnosis of advanced synovial sarcoma (Cohort 1 and Cohort 2) or myxoid liposarcoma /&#xD;
             myxoid round cell liposarcoma (Cohort 1 only) confirmed by cytogenetics.&#xD;
&#xD;
          -  Previously received either an anthracycline or ifosfamide containing regimen.&#xD;
&#xD;
          -  Measurable disease according to RECIST v1.1.&#xD;
&#xD;
          -  HLA-A*02 positive&#xD;
&#xD;
          -  Tumor shows MAGE-A4 expression confirmed by central laboratory.&#xD;
&#xD;
          -  ECOG Performance Status of 0 or1. For subjects aged ≥10 to ≥16 years old:&#xD;
&#xD;
        Lansky Score ≥60%.&#xD;
&#xD;
        • Left ventricular ejection fraction (LVEF) ≥50%.&#xD;
&#xD;
        Note: other protocol defined Inclusion criteria may apply&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  HLA-A*02:05 in either allele&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to fludarabine, cyclophosphamide or other agents used in the study.&#xD;
&#xD;
          -  History of autoimmune or immune mediated disease&#xD;
&#xD;
          -  Symptomatic CNS metastases including leptomeningeal disease.&#xD;
&#xD;
          -  Other prior malignancy that is not considered by the Investigator to be in complete&#xD;
             remission&#xD;
&#xD;
          -  Clinically significant cardiovascular disease&#xD;
&#xD;
          -  Uncontrolled intercurrent illness&#xD;
&#xD;
          -  Active infection with human immunodeficiency virus, hepatitis B virus, hepatitis C&#xD;
             virus, or human T cell leukemia virus&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
        Note: other protocol defined Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deijka Aruajo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD Anderson Cancer Center; Houston TX 77030</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adaptimmune Patient Enquiries</last_name>
    <phone>215-825-9260</phone>
    <email>patients@adaptimmune.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adria Arencibia</last_name>
      <phone>626-218-0721</phone>
      <phone_ext>80721</phone_ext>
      <email>aarencibia@coh.org</email>
    </contact>
    <contact_backup>
      <last_name>Hrpsime Martirosyan</last_name>
      <phone>626-218-2835</phone>
      <email>hmartirosyan@coh.org</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Agulnik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Behnaz Parsien</last_name>
      <phone>650-498-0623</phone>
      <email>behnaza@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Kristen Ganjoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chelsea Mason</last_name>
      <phone>720-848-0289</phone>
      <email>chelsea.mason@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Breelyn Wilky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katharine Sheffield</last_name>
      <phone>904-953-3972</phone>
      <email>sheffield.katharine@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Attia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Lennon</last_name>
      <phone>813-745-4027</phone>
      <email>Christina.Lennon@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Mihaela Druta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University Robert H. Lurie Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Lagocki</last_name>
      <phone>312-695-3527</phone>
      <email>steven.lagocki@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Seth Pollack, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amanda Carbonell</last_name>
      <email>amanda.carbonell@nih.gov</email>
    </contact>
    <contact_backup>
      <last_name>Katie McHugh</last_name>
      <email>katie.mchugh@nih.gov</email>
    </contact_backup>
    <investigator>
      <last_name>John Glod, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Edwin Choy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Falvey</last_name>
      <phone>617-582-9567</phone>
      <email>carolineA_Falvey@dfci.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mike Trailor</last_name>
      <email>MTRAILOR@mgh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>George Demetri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paige Larkin</last_name>
      <phone>734-615-0654</phone>
      <email>crawforp@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Scott Schuetze</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Landeau</last_name>
      <email>landeaum@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Van Tine, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camden Esancy</last_name>
      <phone>212-342-3884</phone>
      <email>ce2331@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Chayanne Solorzano Villegas</last_name>
      <email>cs4018@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gary Schwartz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sam Wheeler</last_name>
      <email>wheelers@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Sandra D'Angelo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassondra Faiella</last_name>
      <phone>614-685-9353</phone>
      <email>Cassondra.Faiella@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>David Liebner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Butler</last_name>
      <email>benjamin.butler@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Vicki Keedy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mamatha Hamumanthaiah</last_name>
      <email>mhanumanthaiah@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Deijka Aruajo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutch</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Dherin</last_name>
      <phone>206-667-3403</phone>
      <email>mdherin@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Michael Wagner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of WI Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>John Charlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Genevieve Mendiola</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>7754</phone_ext>
      <email>Genevieve.mendiola@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Albiruni G Razak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adaptimmune Patient enquiries</last_name>
      <phone>215-825-9260</phone>
      <email>patients@adaptimmune.com</email>
    </contact>
    <investigator>
      <last_name>Jeans-Yves Blay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Haut Leveque, CHU Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adaptimmune patient enquiries</last_name>
      <phone>+1 (215)-825-9260</phone>
      <email>patients@adaptimmune.com</email>
    </contact>
    <investigator>
      <last_name>Edouard Forcade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy Cancer Center</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adaptimmune Patient Enquiries</last_name>
      <phone>1(215)-825-9260</phone>
      <email>patients@Adaptimmune.com</email>
    </contact>
    <investigator>
      <last_name>Axel Le Cesne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <zip>119-129</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Gutierrez</last_name>
      <email>saragutierrez@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Claudia Valverde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Start Madrid-FJD, Fundación Jimѐnez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Ferrero</last_name>
      <phone>34 91 550 4800</phone>
      <email>olga.ferrero@startmadrid.com</email>
    </contact>
    <investigator>
      <last_name>Victor Moreno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esperanza Muñoz</last_name>
      <phone>34955013068</phone>
      <email>espe.m.garcia@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>María Vázquez</last_name>
      <phone>+34955013068</phone>
      <email>mariavazquezonco.huvr@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Irene Carrasco Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLH Cancer Clinical Trials Unit</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Taylor</last_name>
      <email>sarah.tayloe83@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Sandra Strauss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shweta Vyas</last_name>
      <phone>+44 (0) 161 918 2323</phone>
      <email>Shweta.vyas@christie.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Fiona Thistlethwaite, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 9, 2019</study_first_submitted>
  <study_first_submitted_qc>August 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cell Therapy</keyword>
  <keyword>T Cell Therapy</keyword>
  <keyword>SPEAR T Cell</keyword>
  <keyword>Sarcoma</keyword>
  <keyword>MRCLS</keyword>
  <keyword>MAGE A-4</keyword>
  <keyword>Immuno-oncology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Liposarcoma</mesh_term>
    <mesh_term>Sarcoma, Synovial</mesh_term>
    <mesh_term>Liposarcoma, Myxoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

